CDKN2A and uveal melanoma: Russo et al. [18] proposed that mutations of the cyclin-dependent kinase inhibitor 2A (CDKN2A) leading to its inactivation, through promoter methylation or loss of the 9p region, could play an important role in the development and metastatic progression of uveal melanoma, especially with 8q amplification.